These findings, as summarized in Fig. 11, represent the basis of a new immunotherapy strategy of cancer based on PD-L1/PD-1 blockade, which stimulates powerful antitumor immune response mediated by TAMs instead of lymphocytes. The gene discussed is PDCD1; the disease is cancer.